COMPANY PROFILE

Hylomorph

Hylomorph is an innovative Medtech company engineering biomaterials to optimize the interface between implantable medical devices and tissues

Zurich, SwitzerlandFounded 2014Biotech & Life Sciences

Valuation $25–50M Last recorded · 2023

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Hylomorph

Hylomorph, a Swiss-based clinical stage medical device company, is pioneering the development of innovative materials designed to enhance the biocompatibility of implantable medical devices. The company focuses on addressing a critical issue faced by millions of patients worldwide who live with surgical implants. When a patient receives an implant, the body's immune system often reacts by forming a thick layer of fibrotic tissue around the implant. This reaction can lead to complications such as hardening and contraction of the tissue, which can cause discomfort and other health issues.

Read full description

Hylomorph's mission is to minimize these post-surgical complications, thereby improving the quality of life for patients and reducing healthcare costs associated with these complications. The company operates in the medical device market, specifically targeting the segment of implantable devices. Their clients include hospitals, clinics, and healthcare providers who perform surgeries involving implants.

The business model of Hylomorph revolves around the development and commercialization of their proprietary materials. They generate revenue by selling these advanced materials to medical device manufacturers and healthcare institutions. By providing a solution that enhances the biocompatibility of implants, Hylomorph not only helps in reducing the immune response but also extends the lifespan and effectiveness of the implants.

In summary, Hylomorph is transforming the landscape of medical implants by offering a solution that mitigates the body's adverse reactions to foreign objects, thereby ensuring better patient outcomes and more efficient healthcare delivery.

Source: Dealroom company data